Skip to main content
. 2019 Sep 10;23(11):7349–7359. doi: 10.1111/jcmm.14594

Figure 6.

Figure 6

Targeting S1R strengthens the anticancer activity of sorafenib in vivo. A, B, Nude mice were injected subcutaneously with indicated Huh‐7 cells (1 × 107 cells/mouse) and treated with sorafenib (10 mg/kg/i.p., once every other day) and vehicle at day seven for 2 weeks (n = 5 mice/group). Tumour volume was calculated every 3 d. C, D, In parallel, the levels of GSH and indicated genes mRNA in isolated tumours at day 28 were assayed (*P < .05)